A Real Role for Immunotherapy in the Treatment of Advanced Prostate Cancer

Immunotherapy has a major and expanding role in the treatment of cancer, including advanced prostate cancer. Over time there have been a number of naysayers as the immunotherapy Provenge has played the role whipping boy by critics. The common criticism leveled at Provenge can be summed up simply, “It doesn’t work.” The plain truth is [...]

The Well Reviewed Guide to Advanced Prostate Cancer (A Survivor Perspective) Has Been Updated and is Now Available for a free Download

Somehow I have been negligent and not let people know that I have written and posted a major update of my “Guide to Advanced Prostate Cancer.” As in the past, it is available as a free download from the Malecare web site. Helping me to update the book was prostate cancer survivor Craig Pynn and [...]

Malecare Adds A New Teleconference About Immunotherapy and Advanced Prostate Cancer

Malecare announces the addition of our latest and informative teleconference about Immunotherapy and Advanced Prostate Cancer.  Joining me in the conference is Dr. Nicholas J. Vogelzang, M.D., a medical oncologist with the Comprehensive Cancer Centers of Nevada (CCCN) and serves as chair and site research leader, and as medical director of the Developmental Therapeutics Committee and Member [...]

A Correction of A Prior Post – How About Entering the Prostvac-VF Trail and Then Have Provenge?

On March 4th I wrote a post which included a suggestion that combining Provenge and the clinical trial of Prostvac-VF might provide an interesting one-two punch against advanced prostate cancer.  In the post I suggested that it could be interesting to have Provenge and then move immediately on to Prostvac. This was an error, I [...]

Castrate Resistant Prostate Cancer- What To Do Next?

Confusion, confusion and more confusion, that is how I would describe the current decision making process for a man with prostate cancer that has become newly castrate resistant. Just a few years ago the decision tree was clear, castrate resistant, immediately on to chemotherapy with docetaxel. Today, in this treatment space, we have a number [...]

Immune Therapy & A Rising PSA Coupled With Disease Progression – Does It Work?

Why does PSA continue to rise and prostate cancer disease continue to progress (new tumors develop and existing tumors continue to get bigger) when a man has an immune system treatment to go after their prostate cancer? This issue is probably the major marketing hurdle faced by Dendreon’s Provenge and based on the current statistics [...]

Barvarian Nordic Provides A Long Anticipated Update on Their Randomized Phase 3 trial of Prostvac VF

Barvarian Nordic (BN) released some outstanding news a few days ago. According to BN they hope to complete the enrollment in their phase 3, double blind, randomized, placebo controlled, international clinical trial of their cancer vaccine, Prostvac VF. The trial known as PROSPECT is scheduled to be completed with in the next 12 months, unless [...]

Advanced Prostate Cancer Survivors On Androgen Deprivation Therapy Develop Persistent Changes in Immune Responses

I stumbled upon an abstract published at the end of February 2010 that raised a number of questions about hormone therapy (ADT) and its effect on the immune system. Coming out of the starting gate I assumed that ADT would adversely affect the immune system making us prone to falling victim to all sort of [...]

A Video Interview About My Experience at the AACR Meeting in Chicago

Patient Power, a Partner Organization of Malecare, just released a Skype interview they made with me about some aspects of the recent AACR meeting in Chicago. I talk about the exciting results from the Phase II trial of Prostvac, a small phase II study of Pomegranate juice for men with prostate cancer as well as [...]

Bavarian Nordic Initiates Pivotal Phase 3 Trial of PROSTVAC® Prostate Cancer Immunotherapy

Bavarian Nordic A/S (BAVA) announced on November 15, that its subsidiary, BN ImmunoTherapeutics has started the pivotal Phase 3 trial of PROSTVAC® for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The trial is being conducted under a Special Protocol Assessment agreement with the FDA. Notice this trial has the same criteria as [...]